Cargando…

SARS-CoV-2 vaccines: Lights and shadows

Vaccines to prevent acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicit an immune neutralizing response. Some concerns have been raised regarding the safety of SARS-CoV-2 vaccines, largely based on case-reports of serious thromboembolic events after vaccination. Some mechanisms ha...

Descripción completa

Detalles Bibliográficos
Autores principales: Angeli, Fabio, Spanevello, Antonio, Reboldi, Gianpaolo, Visca, Dina, Verdecchia, Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: European Federation of Internal Medicine. Published by Elsevier B.V. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084611/
https://www.ncbi.nlm.nih.gov/pubmed/33966930
http://dx.doi.org/10.1016/j.ejim.2021.04.019
_version_ 1783686188356337664
author Angeli, Fabio
Spanevello, Antonio
Reboldi, Gianpaolo
Visca, Dina
Verdecchia, Paolo
author_facet Angeli, Fabio
Spanevello, Antonio
Reboldi, Gianpaolo
Visca, Dina
Verdecchia, Paolo
author_sort Angeli, Fabio
collection PubMed
description Vaccines to prevent acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicit an immune neutralizing response. Some concerns have been raised regarding the safety of SARS-CoV-2 vaccines, largely based on case-reports of serious thromboembolic events after vaccination. Some mechanisms have been suggested which might explain the adverse cardiovascular reactions to SARS-CoV-2 vaccines. Different vaccine platforms are currently available which include live attenuated vaccines, inactivated vaccines, recombinant protein vaccines, vector vaccines, DNA vaccines and RNA vaccines. Vaccines increase the endogenous synthesis of SARS-CoV-2 Spike proteins from a variety of cells. Once synthetized, the Spike proteins assembled in the cytoplasma migrate to the cell surface and protrude with a native-like conformation. These proteins are recognized by the immune system which rapidly develops an immune response. Such response appears to be quite vigorous in the presence of DNA vaccines which encode viral vectors, as well as in subjects who are immunized because of previous exposure to SARS-CoV-2. The resulting pathological features may resemble those of active coronavirus disease. The free-floating Spike proteins synthetized by cells targeted by vaccine and destroyed by the immune response circulate in the blood and systematically interact with angiotensin converting enzyme 2 (ACE2) receptors expressed by a variety of cells including platelets, thereby promoting ACE2 internalization and degradation. These reactions may ultimately lead to platelet aggregation, thrombosis and inflammation mediated by several mechanisms including platelet ACE2 receptors. Whereas Phase III vaccine trials generally excluded participants with previous immunization, vaccination of huge populations in the real life will inevitably include individuals with preexisting immunity. This might lead to excessively enhanced inflammatory and thrombotic reactions in occasional subjects. Further research is urgently needed in this area.
format Online
Article
Text
id pubmed-8084611
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher European Federation of Internal Medicine. Published by Elsevier B.V.
record_format MEDLINE/PubMed
spelling pubmed-80846112021-05-03 SARS-CoV-2 vaccines: Lights and shadows Angeli, Fabio Spanevello, Antonio Reboldi, Gianpaolo Visca, Dina Verdecchia, Paolo Eur J Intern Med Review Article Vaccines to prevent acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection elicit an immune neutralizing response. Some concerns have been raised regarding the safety of SARS-CoV-2 vaccines, largely based on case-reports of serious thromboembolic events after vaccination. Some mechanisms have been suggested which might explain the adverse cardiovascular reactions to SARS-CoV-2 vaccines. Different vaccine platforms are currently available which include live attenuated vaccines, inactivated vaccines, recombinant protein vaccines, vector vaccines, DNA vaccines and RNA vaccines. Vaccines increase the endogenous synthesis of SARS-CoV-2 Spike proteins from a variety of cells. Once synthetized, the Spike proteins assembled in the cytoplasma migrate to the cell surface and protrude with a native-like conformation. These proteins are recognized by the immune system which rapidly develops an immune response. Such response appears to be quite vigorous in the presence of DNA vaccines which encode viral vectors, as well as in subjects who are immunized because of previous exposure to SARS-CoV-2. The resulting pathological features may resemble those of active coronavirus disease. The free-floating Spike proteins synthetized by cells targeted by vaccine and destroyed by the immune response circulate in the blood and systematically interact with angiotensin converting enzyme 2 (ACE2) receptors expressed by a variety of cells including platelets, thereby promoting ACE2 internalization and degradation. These reactions may ultimately lead to platelet aggregation, thrombosis and inflammation mediated by several mechanisms including platelet ACE2 receptors. Whereas Phase III vaccine trials generally excluded participants with previous immunization, vaccination of huge populations in the real life will inevitably include individuals with preexisting immunity. This might lead to excessively enhanced inflammatory and thrombotic reactions in occasional subjects. Further research is urgently needed in this area. European Federation of Internal Medicine. Published by Elsevier B.V. 2021-06 2021-04-30 /pmc/articles/PMC8084611/ /pubmed/33966930 http://dx.doi.org/10.1016/j.ejim.2021.04.019 Text en © 2021 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Review Article
Angeli, Fabio
Spanevello, Antonio
Reboldi, Gianpaolo
Visca, Dina
Verdecchia, Paolo
SARS-CoV-2 vaccines: Lights and shadows
title SARS-CoV-2 vaccines: Lights and shadows
title_full SARS-CoV-2 vaccines: Lights and shadows
title_fullStr SARS-CoV-2 vaccines: Lights and shadows
title_full_unstemmed SARS-CoV-2 vaccines: Lights and shadows
title_short SARS-CoV-2 vaccines: Lights and shadows
title_sort sars-cov-2 vaccines: lights and shadows
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8084611/
https://www.ncbi.nlm.nih.gov/pubmed/33966930
http://dx.doi.org/10.1016/j.ejim.2021.04.019
work_keys_str_mv AT angelifabio sarscov2vaccineslightsandshadows
AT spanevelloantonio sarscov2vaccineslightsandshadows
AT reboldigianpaolo sarscov2vaccineslightsandshadows
AT viscadina sarscov2vaccineslightsandshadows
AT verdecchiapaolo sarscov2vaccineslightsandshadows